Denali Therapeutics (NASDAQ:DNLI) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded Denali Therapeutics from “sell” to “hold,” while the broader analyst consensus remains “Moderate Buy,” with 13 Buy, two Hold and one Sell rating and an average price target of $35.85.
• Several firms raised their price targets, including UBS to $34, Deutsche Bank to $35 and Morgan Stanley to $36; shares opened at $19.72 and have traded between $12.58 and $27.30 over the past year.
• Denali reported a quarterly loss of $0.68 per share, missing estimates by $0.17, although revenue of $3.60 million exceeded expectations. Institutional investors own 92.92% of the stock, led by a new $360.8 million BlackRock position.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) was upgraded by analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Saturday, Wall Street Zen reports.

DNLI has been the subject of several other research reports. UBS Group upped their price target on Denali Therapeutics from $25.00 to $34.00 and gave the stock a "buy" rating in a report on Friday, August 7th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Denali Therapeutics from $31.00 to $35.00 and gave the stock a "buy" rating in a report on Thursday, July 16th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Denali Therapeutics in a report on Friday, July 17th. Morgan Stanley raised their price target on shares of Denali Therapeutics from $35.00 to $36.00 and gave the company an "overweight" rating in a research report on Thursday, July 23rd. Finally, Sanford C. Bernstein restated a "hold" rating on shares of Denali Therapeutics in a report on Monday, June 22nd. Thirteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $35.85.

Denali Therapeutics Price Performance

Shares of NASDAQ DNLI opened at $19.72 on Friday. The stock has a market cap of $3.15 billion, a price-to-earnings ratio of -6.94 and a beta of 1.01. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.32 and a current ratio of 8.37. Denali Therapeutics has a fifty-two week low of $12.58 and a fifty-two week high of $27.30. The firm's 50-day simple moving average is $23.42 and its 200 day simple moving average is $21.87.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.17). The business had revenue of $3.60 million during the quarter, compared to analysts' expectations of $2.15 million. During the same period in the prior year, the company earned ($0.72) earnings per share. As a group, research analysts anticipate that Denali Therapeutics will post -2.67 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Alexander O. Schuth sold 2,857 shares of the firm's stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total transaction of $71,624.99. Following the completion of the sale, the insider owned 281,763 shares in the company, valued at approximately $7,063,798.41. This trade represents a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 9.70% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of DNLI. BlackRock Inc. bought a new stake in shares of Denali Therapeutics in the 2nd quarter worth approximately $360,759,000. Temasek Holdings Private Ltd raised its stake in shares of Denali Therapeutics by 30.9% in the fourth quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company's stock valued at $115,784,000 after buying an additional 1,657,142 shares during the period. Norges Bank purchased a new position in shares of Denali Therapeutics during the 4th quarter valued at $84,525,000. Dimensional Fund Advisors LP lifted its position in shares of Denali Therapeutics by 13.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,692,175 shares of the company's stock valued at $51,687,000 after buying an additional 317,872 shares during the last quarter. Finally, Fisher Asset Management LLC lifted its position in shares of Denali Therapeutics by 58.7% during the 4th quarter. Fisher Asset Management LLC now owns 2,589,403 shares of the company's stock valued at $42,751,000 after buying an additional 957,907 shares during the last quarter. 92.92% of the stock is owned by institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc is a biotechnology company focused on discovering and developing medicines for patients with neurodegenerative diseases. The company is headquartered in South San Francisco, California, and was founded in 2013 by a team that included Chief Executive Officer Ryan Watts.

Denali's research is built around its blood-brain barrier transport technologies, which are designed to help therapeutic molecules reach the brain. The company applies these technologies to potential treatments for conditions including Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, lysosomal storage disorders and other neurodegenerative diseases.

Its pipeline has included investigational therapies directed at targets such as LRRK2, TREM2 and RIPK1, as well as enzyme-replacement approaches intended to improve delivery of treatments to the central nervous system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.